Author

E. Peuhu

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Cell Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 4 Assay:proteomics· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell signaling & trafficking· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1

Frequent Co-Authors

J. Ivaska· 5 shared C. Guzman· 2 shared G. Jacquemet· 2 shared I. Paatero· 2 shared J. Lilja· 2 shared M. Georgiadou· 2 shared A. Cvrljevic· 1 shared A. Elosegui-Artola· 1 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCell Biology

J. Ivaska

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Targeting a broad spectrum of KRAS-mutant cancers by hyperactivation-induced cell death

J. Lilja, J. Kaivola, J. R. W. Conway, J. Vuorio, H. Parkkola, P. Roivas, T. Varila, G. Jacquemet, E. Peuhu, E. Wang, U. Pentikäinen, I. M. D. Posada, H. Hamidi, A. K. Najumudeen, O. J. Sansom, , J. Ivaska

This study identifies SHANK3 as a RAS interactor that limits oncogenic KRAS signaling, and shows that disrupting its interaction with KRAS induces cell death in KRAS-mutant cancers.

bioRxiv · Sep 21, 2022 · PreprintCancer Biology

Filopodia-mediated basement membrane assembly at pre-invasive tumor boundaries

E. Peuhu, G. Jacquemet, C. L. Scheele, A. Isomursu, I. Paatero, K. Thol, M. Georgiadou, C. Guzman, S. Koskinen, A. Laiho, L. L. Elo, P. Boström, P. Hartiala, J. van Rheenen, J. Ivaska

This study shows MYO10 promotes BM assembly in DCIS to limit invasion but facilitates cancer cell dissemination in invasive breast cancer.

bioRxiv · Oct 22, 2021 · PreprintCell Biology

Sortilin-related receptor is a druggable therapeutic target in breast cancer

H. Al-Akhrass, M. Pietilä, J. Lilja, E.-M. Vesilahti, J. M. Anttila, H. M. Haikala, P. M. Munne, J. Klefström, E. Peuhu, J. Ivaska

This study shows that targeting SorLA with a monoclonal antibody can overcome HER2 resistance in breast cancer, both in vitro and in vivo.

bioRxiv · Mar 9, 2021Cancer Biology

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

A. Laine, S. Nagelli, C. Farrington, U. Butt, A. Cvrljevic, J. Vainonen, T. Gronroos, P. Gautam, S. Khan, H. Sihto, X. Qiao, D. Connolly, P. Kronqvist, J. Maurer, K. Wennerberg, , J. Westermarck

This study identifies CIP2A as a subtype-specific driver of DNA damage-induced basal-like breast cancer, showing its role in checkpoint signaling and therapeutic vulnerability.

bioRxiv · Aug 27, 2020Cancer Biology

Integrin binding dynamics modulate ligand-specific mechanosensing in mammary gland fibroblasts

M. Lerche, A. Elosegui-Artola, J. Z. Kechagia, C. Guzman, M. Georgiadou, D. Gulberg, P. Roca-Cusachs, E. Peuhu, J. Ivaska

This study shows that SHARPIN regulates collagen-specific mechanosensing in mammary fibroblasts by modulating integrin 11β1 activity and force transmission.

bioRxiv · Dec 20, 2019Cell Biology

SORLA-driven endosomal trafficking regulates the oncogenic fitness of HER2

M. Pietila, P. Sahgal, E. Peuhu, N. Jantti, I. Paatero, O. M. Andersen, A. Padzik, M. Blomqvist, I. Saarinen, P. Bostrom, P. Taimen, J. Ivaska

This study shows SORLA regulates HER2 trafficking, affecting its oncogenic activity and response to therapy.

bioRxiv · Apr 11, 2018Cell Biology